Answer from: Radiation Oncologist at Community Practice
Neoadjuvant chemotherapy is controversial in extremity/trunk STS.Generally speaking, grade 2/3 tumors that are ≥5 cm are at high-risk for distant recurrence despite ~90% local control. For these patients, you can consider neoadjuvant chemoRT. When using neoadjuvant chemoRT, the more common a...
Answer from: Medical Oncologist at Academic Institution
We sometimes now give concurrent chemoxrt for limb sarcoma as was done on ARST1321.
ARST1321 was a phase 3 clinical trial in which patients with soft tissue sarcoma received preoperative doxorubicin+ifosfamide and concurrent radiation with or without concurrent pazopanib. Postoperatively, stu...